Safe Harbor Statement
This presentation contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed due to a number of factors, including risks that we may require more cash for operating activities than anticipated; risks and uncertainties in FDA requirements for SYMLIN and exenatide approval, and that approval, if any, may be delayed and/or limited; risks inherent in the drug discovery and development process; and risks and uncertainties regarding our ability to commercialize our product candidates. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Form 10-K for 2003, and our recently filed registration statement on Form S-3 under the heading "Risk Factors Related to Our Business."